News coverage about Synergy Pharmaceuticals (NASDAQ:SGYP) has been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.6165844177815 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Synergy Pharmaceuticals, Inc. Expected to Earn Q1 2018 Earnings of ($0.16) Per Share (SGYP) (americanbankingnews.com)
- Synergy Pharmaceuticals Inc. (SGYP)- Stocks Rallying on Performance Valuation – NASDAQ Times (nasdaqtimes.com)
- Oppenheimer Casts 3Q Predictions: Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Synergy Pharmaceuticals Inc … – Smarter Analyst (smarteranalyst.com)
- Synergy Pharmaceuticals: Sales Of Trulance Trending Well – Seeking Alpha (seekingalpha.com)
- Synergy Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SGYP) : October 4, 2017 (finance.yahoo.com)
Synergy Pharmaceuticals (SGYP) traded down 0.1667% during mid-day trading on Thursday, hitting $3.2346. The stock had a trading volume of 629,466 shares. The firm’s market cap is $727.64 million. The stock has a 50 day moving average of $2.94 and a 200-day moving average of $3.78. Synergy Pharmaceuticals has a 1-year low of $2.56 and a 1-year high of $7.15.
Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.08). The business had revenue of $2.31 million during the quarter, compared to analysts’ expectations of $1.98 million. During the same quarter last year, the firm earned ($0.23) EPS. Analysts predict that Synergy Pharmaceuticals will post ($1.16) EPS for the current fiscal year.
A number of research analysts have issued reports on SGYP shares. HC Wainwright reiterated a “buy” rating and set a $8.00 price target (down previously from $15.00) on shares of Synergy Pharmaceuticals in a research report on Monday, September 25th. They noted that the move was a valuation call. Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 price target on shares of Synergy Pharmaceuticals in a research report on Friday, September 8th. Zacks Investment Research lowered Synergy Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Canaccord Genuity reiterated a “buy” rating and set a $13.00 price target on shares of Synergy Pharmaceuticals in a research report on Monday, July 10th. Finally, BidaskClub lowered Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Three analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $8.90.
TRADEMARK VIOLATION WARNING: “Synergy Pharmaceuticals (SGYP) Receives Daily Media Impact Score of 0.14” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2017/10/12/synergy-pharmaceuticals-sgyp-receives-daily-media-impact-score-of-0-14.html.
In other Synergy Pharmaceuticals news, major shareholder Paulson & Co. Inc. sold 26,287 shares of the stock in a transaction on Monday, August 7th. The stock was sold at an average price of $3.77, for a total value of $99,101.99. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.80% of the stock is currently owned by company insiders.
Synergy Pharmaceuticals Company Profile
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.